Drugs that contain Paclitaxel

1. List of Abraxane drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7923536 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents
Dec, 2023

(10 months from now)

US8138229 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents
Dec, 2023

(10 months from now)

US8314156 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents
Dec, 2023

(10 months from now)

US7923536

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents
Jun, 2024

(1 year, 4 months from now)

US8314156

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents
Jun, 2024

(1 year, 4 months from now)

US8138229

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents
Jun, 2024

(1 year, 4 months from now)

US7820788 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents
Oct, 2024

(1 year, 8 months from now)

US7820788

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents
Apr, 2025

(2 years from now)

US7758891 ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2026

(3 years from now)

US9101543 ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2026

(3 years from now)

US8268348 ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2026

(3 years from now)

US8034375 ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(3 years from now)

US9101543

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(3 years from now)

US8268348

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(3 years from now)

US7758891

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(3 years from now)

US8034375

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2027

(4 years from now)

US9597409 ABRAXIS BIOSCIENCE Methods of treating cancer
Mar, 2032

(9 years from now)

US9393318 ABRAXIS BIOSCIENCE Methods of treating cancer
Mar, 2032

(9 years from now)

US9393318

(Pediatric)

ABRAXIS BIOSCIENCE Methods of treating cancer
Sep, 2032

(9 years from now)

US9597409

(Pediatric)

ABRAXIS BIOSCIENCE Methods of treating cancer
Sep, 2032

(9 years from now)

US9511046 ABRAXIS BIOSCIENCE Methods of treating pancreatic cancer
Jan, 2034

(10 years from now)

US9511046

(Pediatric)

ABRAXIS BIOSCIENCE Methods of treating pancreatic cancer
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M Dec 6, 2022
Pediatric Exclusivity (PED) Jun 6, 2023

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of pancreatic cancer; Treatment of lung cancer; Treatment of breast cancer

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic